UBS AM
VYGR icon

UBS AM’s Voyager Therapeutics VYGR Stock Holding History

UBS AM’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3K Buy
+595
New +$2.34K ﹤0.01% 3571
2023
Q1 		– Sell
-48,900
Closed -$298K – 2720
2022
Q4 		$298K Buy
+48,900
New +$278K ﹤0.01% 2330
2021
Q2 		– Sell
-26,231
Closed -$124K – 2781
2021
Q1 		$124K Buy
26,231
+12,222
+87% +$83.3K ﹤0.01% 2586
2020
Q4 		$100K Hold
14,009
– – ﹤0.01% 2534
2020
Q3 		$149K Hold
14,009
– – ﹤0.01% 2438
2020
Q2 		$177K Hold
14,009
– – ﹤0.01% 2412
2020
Q1 		$128K Sell
14,009
-279,967
-95% -$3.21M ﹤0.01% 2368
2019
Q4 		$4.1M Sell
293,976
-18,945
-6% -$275K ﹤0.01% 1277
2019
Q3 		$5.39M Buy
312,921
+2,839
+0.9% +$59.6K ﹤0.01% 1178
2019
Q2 		$8.44M Buy
310,082
+10,688
+4% +$245K 0.01% 1008
2019
Q1 		$5.73M Sell
299,394
-13,505
-4% -$176K ﹤0.01% 1101
2018
Q4 		$2.94M Sell
312,899
-22,772
-7% -$292K ﹤0.01% 1279
2018
Q3 		$6.35M Buy
335,671
+7,841
+2% +$150K ﹤0.01% 1066
2018
Q2 		$6.41M Buy
327,830
+60,728
+23% +$1.2M ﹤0.01% 1066
2018
Q1 		$5.02M Sell
267,102
-1,053
-0.4% -$22.8K ﹤0.01% 1145
2017
Q4 		$4.45M Buy
+268,155
New +$4.6M ﹤0.01% 1159

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS AM's VYGR Position: Q1 2026 in Review

UBS AM opened a new position in Voyager Therapeutics (VYGR) in Q1 2026: 595 shares worth $2.3K. The stake represents ﹤0.01% of the portfolio and ranks #3571 among its holdings. This is a return to the name: UBS AM previously reported a position in VYGR as recently as Q4 2022.

UBS AM first reported a position in VYGR in Q4 2017 and has held it in 16 quarters since. The position peaked at $8.44M in Q2 2019. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • UBS AM held 595 shares of Voyager Therapeutics worth $2.3K as of Q1 2026.
  • Voyager Therapeutics was a new UBS AM position in Q1 2026.
  • Voyager Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3571 holding.
  • UBS AM first reported a position in Voyager Therapeutics in Q4 2017 and has held it in 16 quarters since.
  • UBS AM's Voyager Therapeutics position peaked at $8.44M in Q2 2019.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.